ArticleJournal of neuro-oncology2026
α-Synuclein suppresses glioma progression through the CDH13-JNK/c-Jun pathway.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeGliomas are highly invasive primary brain tumors, and additional biomarkers are needed to improve prognostic stratification and clarify the mechanisms underlying tumor invasion. Although α-synuclein (α-syn), encoded by SNCA, is a central protein in neurodegenerative disease, its role in glioma remains poorly defined.
methodsSNCA/α-syn expression was evaluated in glioma specimens from Beijing Tiantan Hospital and in the Chinese Glioma Genome Atlas and The Cancer Genome Atlas cohorts. Associations with clinicopathological characteristics, molecular features, and overall survival were analyzed. Gain- and loss-of-function experiments were performed in U87 cells and patient-derived glioma stem-like cells (GSLCs), followed by proliferation, migration, invasion, and pathway-rescue assays. An orthotopic xenograft model was used to assess tumor growth and survival in vivo.
resultsSNCA/α-syn expression was lower in high-grade gliomas and was associated with favorable molecular features and prolonged survival. α-Syn overexpression inhibited glioma cell proliferation, migration, and invasion, whereas α-syn knockdown promoted proliferation and invasion in GSLCs. Mechanistically, α-syn increased CDH13 expression, activated JNK/c-Jun signaling, and reduced MMP3 and MMP9 expression. CDH13 knockdown or JNK inhibition attenuated these effects and restored glioma cell migration and invasion. In vivo, α-syn overexpression suppressed orthotopic tumor growth and prolonged survival.
conclusionHigh SNCA/α-syn expression is associated with favorable prognosis, whereas α-syn functions as a suppressor of glioma progression, at least partly through the CDH13-JNK/c-Jun axis.
Indexed as
Identifiers
42678647What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.